Literature DB >> 19496626

Strategies to control trachoma.

Anu A Mathew1, Angus Turner, Hugh R Taylor.   

Abstract

Trachoma is a significant public health problem that is endemic in 57 countries, affecting 40.6 million people and contributing to 4% of the global burden of blindness. Repeated episodes of infection from Chlamydia trachomatis lead to long-term inflammation, scarring of the tarsal conjunctiva and distortion of the upper eyelid with in-turning of eyelashes that abrade the surface of the globe. This constant abrasion, in turn, can cause irreversible corneal opacity and blindness. The Alliance for the Global Elimination of Trachoma by 2020 (GET2020) has adopted the SAFE (Surgery, Antibiotics, Facial cleanliness and Environmental improvement) strategy as the main action against trachoma. Trichiasis surgery reduces the risk of blindness by reversing the in-turning of eyelashes and also improves the quality of life from non-visual symptoms. However, future efforts need to aim at increasing accessibility to surgery and improving acceptance. Antibacterials are required to reduce the burden of infection. Oral azithromycin is as close to the perfect antibacterial as we will get for mass distribution: it is safe, requires only a single oral dose, treatment is usually repeated every 6-12 months, resistance is not seen as a problem, and cost is not a limiting factor with a large donation programme and newer generic versions of the drug. Future focus should be on the details of antibacterial distribution such as coverage, frequency of distribution and target population. The promotion of facial cleanliness through education may be the key to trachoma elimination as it will stop the frequent exchange of infected ocular secretions and thus reduce the transmission of infection. However, innovative methods are required to translate health education and promotion activities into sustainable changes in hygiene behaviour. Environmental improvements should focus on the barriers to achieving facial cleanliness and cost-effective means need to be identified. There are a number of countries already eligible for certification of trachoma elimination and if current momentum continues, blinding trachoma can be eliminated by the year 2020.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19496626     DOI: 10.2165/00003495-200969080-00002

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  114 in total

1.  Alterations in the conjunctival bacterial flora following a single dose of azithromycin in a trachoma endemic area.

Authors:  K C Chern; S K Shrestha; V Cevallos; H L Dhami; P Tiwari; L Chern; J P Whitcher; T M Lietman
Journal:  Br J Ophthalmol       Date:  1999-12       Impact factor: 4.638

2.  Global elimination of trachoma: how frequently should we administer mass chemotherapy?

Authors:  T Lietman; T Porco; C Dawson; S Blower
Journal:  Nat Med       Date:  1999-05       Impact factor: 53.440

3.  Return to Alma-Ata.

Authors:  Margaret Chan
Journal:  Lancet       Date:  2008-09-13       Impact factor: 79.321

4.  Risk factors for trachoma in Mali.

Authors:  J-F Schémann; D Sacko; D Malvy; G Momo; L Traore; O Bore; S Coulibaly; A Banou
Journal:  Int J Epidemiol       Date:  2002-02       Impact factor: 7.196

5.  Latrine ownership as a protective factor in inflammatory trachoma in Egypt.

Authors:  P Courtright; J Sheppard; S Lane; A Sadek; J Schachter; C R Dawson
Journal:  Br J Ophthalmol       Date:  1991-06       Impact factor: 4.638

6.  Field evaluation of a rapid point-of-care assay for targeting antibiotic treatment for trachoma control: a comparative study.

Authors:  Claude-Edouard C Michel; Anthony W Solomon; Jose P V Magbanua; Patrick A Massae; Ling Huang; Jonaice Mosha; Sheila K West; Elpidio C B Nadala; Robin Bailey; Craig Wisniewski; David C W Mabey; Helen H Lee
Journal:  Lancet       Date:  2006-05-13       Impact factor: 79.321

7.  Does the diagnosis of trachoma adequately identify ocular chlamydial infection in trachoma-endemic areas?

Authors:  Mariko Bird; Chandler R Dawson; Julius S Schachter; Yinghui Miao; Ahmed Shama; Ahmed Osman; Ahmad Bassem; Thomas M Lietman
Journal:  J Infect Dis       Date:  2003-04-30       Impact factor: 5.226

8.  Assessment of herd protection against trachoma due to repeated mass antibiotic distributions: a cluster-randomised trial.

Authors:  Jenafir I House; Berhan Ayele; Travis C Porco; Zhaoxia Zhou; Kevin C Hong; Teshome Gebre; Kathryn J Ray; Jeremy D Keenan; Nicole E Stoller; John P Whitcher; Bruce D Gaynor; Paul M Emerson; Thomas M Lietman
Journal:  Lancet       Date:  2009-03-28       Impact factor: 79.321

9.  Long term outcome of trichiasis surgery in the Gambia.

Authors:  M J Burton; R J C Bowman; H Faal; E A N Aryee; U N Ikumapayi; N D E Alexander; R A Adegbola; S K West; D C W Mabey; A Foster; G J Johnson; R L Bailey
Journal:  Br J Ophthalmol       Date:  2005-05       Impact factor: 4.638

10.  Infection with Chlamydia trachomatis after mass treatment of a trachoma hyperendemic community in Tanzania: a longitudinal study.

Authors:  Sheila K West; Beatriz Munoz; Harran Mkocha; Martin J Holland; Aura Aguirre; Anthony W Solomon; Allen Foster; Robin L Bailey; David C W Mabey
Journal:  Lancet       Date:  2005-10-08       Impact factor: 79.321

View more
  15 in total

Review 1.  Understanding the role of aldose reductase in ocular inflammation.

Authors:  U C S Yadav; S K Srivastava; K V Ramana
Journal:  Curr Mol Med       Date:  2010-08       Impact factor: 2.222

Review 2.  Control of neglected tropical diseases needs a long-term commitment.

Authors:  Yaobi Zhang; Chad MacArthur; Likezo Mubila; Shawn Baker
Journal:  BMC Med       Date:  2010-10-29       Impact factor: 8.775

Review 3.  Azithromycin 1.5% ophthalmic solution: in purulent bacterial or trachomatous conjunctivitis.

Authors:  Karly P Garnock-Jones
Journal:  Drugs       Date:  2012-02-12       Impact factor: 9.546

4.  Trachoma rapid assessments in Unity and Northern Bahr-el-Ghazal States, Southern Sudan.

Authors:  Emily Robinson; Lucia W Kur; Aggrey Ndyaba; Mounir Lado; Juma Shafi; Emmanuel Kabare; R Scott McClelland; Jan H Kolaczinski
Journal:  PLoS One       Date:  2010-10-01       Impact factor: 3.240

5.  Integrated implementation of programs targeting neglected tropical diseases through preventive chemotherapy: identifying best practices to roll out programs at national scale.

Authors:  Christy Hanson; Angela Weaver; Kathryn L Zoerhoff; Achille Kabore; Mary Linehan; Amy Doherty; Dirk Engels; Lorenzo Savioli; Eric A Ottesen
Journal:  Am J Trop Med Hyg       Date:  2012-03       Impact factor: 2.345

6.  Prevalence of trachoma in unity state, South Sudan: results from a large-scale population-based survey and potential implications for further surveys.

Authors:  Tansy Edwards; Jennifer Smith; Hugh J W Sturrock; Lucia W Kur; Anthony Sabasio; Timothy P Finn; Mounir Lado; Danny Haddad; Jan H Kolaczinski
Journal:  PLoS Negl Trop Dis       Date:  2012-04-10

7.  A Community-based Eye Care Intervention in Southern Egypt: Impact on Trachomatous Trichiasis Surgical Coverage.

Authors:  Ahmed Mousa; Paul Courtright; Arminee Kazanjian; Ken Bassett
Journal:  Middle East Afr J Ophthalmol       Date:  2015 Oct-Dec

Review 8.  The added value of water, sanitation, and hygiene interventions to mass drug administration for reducing the prevalence of trachoma: a systematic review examining.

Authors:  Anyess Travers; Sheryl Strasser; Stephanie L Palmer; Christine Stauber
Journal:  J Environ Public Health       Date:  2013-08-07

Review 9.  Evidence for integrating eye health into primary health care in Africa: a health systems strengthening approach.

Authors:  Rènée du Toit; Hannah B Faal; Daniel Etya'ale; Boateng Wiafe; Ingrid Mason; Ronnie Graham; Simon Bush; Wanjiku Mathenge; Paul Courtright
Journal:  BMC Health Serv Res       Date:  2013-03-18       Impact factor: 2.655

Review 10.  The impact of climatic risk factors on the prevalence, distribution, and severity of acute and chronic trachoma.

Authors:  Anita Ramesh; Sari Kovats; Dominic Haslam; Elena Schmidt; Clare E Gilbert
Journal:  PLoS Negl Trop Dis       Date:  2013-11-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.